Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2025

Summary of Significant Accounting Policies

Summary of the items included within net loss regularly provided to the CODM

	Three months ended September 30,				Nine months ended September 30,
	2025		2024		2025		2024
Revenue	$	20,689	$	18,957	$	59,406	$	51,651
Cost of revenue (excluding amortization of intangible assets)		6,625		6,004		18,535		16,099
Amortization of intangible assets		95		95		285		285
Gross profit		13,969		12,858		40,586		35,267
Sales and marketing:
Sales and sales management		10,452		11,854		33,281		34,276
International		1,329		1,200		4,137		3,626
Other sales and marketing (a)		3,446		3,418		11,274		12,789
Total sales and marketing		15,227		16,472		48,692		50,691
General and Administrative:
Finance and Legal		1,842		1,886		5,761		5,747
Other General and administrative (b)		2,106		1,797		6,149		5,386
Total general and administrative		3,948		3,683		11,910		11,133
Research and Development:
Clinical		873		1,026		2,654		3,162
Regulatory and quality		468		347		1,334		1,108
Other research and development (c)		1,007		695		3,103		2,514
Total research and development		2,348		2,068		7,091		6,784
Gain on sale of product line		—		—		—		7,580
Other segment items (d)		(1,049)		(1,007)		(2,683)		(2,872)
Net loss	$	(8,603)	$	(10,372)	$	(29,790)	$	(28,633)
(a) Other sales and marketing includes strategy, analytics and allocated facility expenses.
(b) Other general and administrative includes executive, human resources, information technology and allocated facility expenses.
(c) Other research and development includes engineering and allocated facility expenses.
(d) Other segment items include other operating income and other expenses as disclosed in the consolidated statements of operations and comprehensive loss; interest expense, other income and income tax expense.

Schedule of reconciliation of all captions of cash, cash equivalents and restricted cash

	September 30,		September 30,
	2025		2024
Cash and cash equivalents	$	29,713	$	17,301
Restricted cash		250		265
Total cash and cash equivalents and restricted cash shown in statements of cash flows	$	29,963	$	17,566

Disaggregation of Revenue

The following table presents revenue disaggregated by the Company’s portfolio of products (in thousands):

	Three months ended September 30,				Nine months ended September 30,
	2025		2024		2025		2024
OviTex	$	13,206	$	12,463	$	37,802	$	34,122
OviTex PRS		7,079		6,313		20,456		17,054
Other		404		181		1,148		475
Total revenue	$	20,689	$	18,957	$	59,406	$	51,651

Schedule of fair value of assets and liabilities measured on recurring basis

The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):

	Fair value measurement at reporting date using
	Quoted prices in
	active markets		Significant other		Significant
	for identical		observable		unobservable
	assets		inputs		inputs
	(Level 1)		(Level 2)		(Level 3)
September 30, 2025:
Cash equivalents – money market fund	$	26,858	$	—	$	—
December 31, 2024:
Cash equivalents – money market fund	$	48,131	$	—	$	—

Schedule of dilutive securities excluded

	Nine months ended September 30,
	2025	2024
Stock options	2,655,472	2,128,862
Unvested restricted stock units	1,309,701	971,439
Common stock warrants	88,556	88,556
Total	4,053,729	3,188,857